The Board of the EuroQol Research Foundation regularly reviews the EQ-5D user license policy. Recently, a decision has been made to extend free use to all non-commercial users. Therefore, as of today, 18 January 2019, the EuroQol Research Foundation will…
EuroQol is continuously working to keep its IT infrastructure up-to-date. As a result, the EQ-5D registration form will be not available between: Thursday January 24th – 06:00 CET and Friday January 25th – 23:59 CET, due to a Salesforce migration.…
We are pleased to announce that EuroQol is hosting its 1st EuroQol Asia Academy Meeting in Guangzhou, China on 11-12 June 2019. The aim of this meeting edition is to support methodological studies in the region by bringing the EQ-5D researchers…
The EuroQol Office published a new version of the EQ-5D-3L User Guide, which is is now available for download at the EuroQol website: A change to the EQ-5D-3L, reflected in this User Guide update, has been made to the paper self-complete…
The following is an update on the current situation regarding the EQ-5D-5L value set for England. The EQ-5D-5L value set for England was published in 2018. Since then, in line with UK government quality assurance requirements, a first independent validation…
The EQ-5D has been used in clinical trials, population studies, and real world clinical settings for over 25 years and interest in using the instrument remains as strong as ever. From 1 October 2017 to 30 September 2018, 4,922 requests…
The EuroQol Office team is based in Rotterdam, the Netherlands, and supports the EuroQol Research Foundation, the EuroQol Group Association and its members. We recently produced a brief film on the EuroQol Office team, see below.
A recent literature search, supplemented with information provided by EuroQol members, revealed that EQ-5D is the recommended tool for use in cost-utility analysis by a number of Health Technology Assessment bodies around the globe (including Colombia, Czech Republic, England and…
The EuroQol Group wishes to warmly congratulate Professor Nancy Devlin on being elected as President-elect (2018-19) of The International Society for Pharmacoeconomics and Outcomes Research (ISPOR). As well as Director of research at the Office of Health Economics in the…